English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

As one of the most common tumors in the urogenital system, bladder carcinoma (BC) is the second leading cause of death (1). To calculate mortality, the number of patients with BC is estimated to be more than 160,000 every year. For the past 20 years, the incidence of BC has been rising, which ranks the 7th in male and the 17th in female worldwide (2). Bladder transitional cell carcinoma (BTCC) is the most common malignancy in the bladder and accounts for 90% of all malignant bladder tumors (3,4). At present, although the mechanism of occurrence and Original Article

Expression and correlation of Bmi-1, AEG-1 and FHIT in bladder transitional cell carcinoma